Correspondence 0001213900-23-022375 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: March 23, 2023 · CIK: 0001601936 · Accession: 0001213900-23-022375
AI Filing Summary & Sentiment
File numbers found in text: 333-269823
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
March 23, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 p.m. Eastern Time on Tuesday, March 28, 2023, or as soon thereafter as is practicable.
Please call Alexander Dinur of Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
March 23, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred
to above be accelerated so that it will be declared effective at 5:00 p.m. Eastern Time on Tuesday, March 28, 2023, or as soon thereafter
as is practicable.
Please call Alexander Dinur
of Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer